AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (548.3 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Rapid Communication | Open Access

CXCL13 shapes tumor immune microenvironment in ovarian cancer with homologous recombination deficiency

Yue Dinga,1, Zheng Yeb,1, Bo Dinga, Songwei Fenga, Furong Duc, Xuejiao Mac, Xiaoxuan Wangc, Yang Shena( )
Department of Obstetrics and Gynaecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu 210008, China
State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, Jiangsu 210096, China
State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, Jiangsu 210042, China

Peer review under responsibility of Chongqing Medical University.

1 These authors contributed equally to this work and shared the first authorship.

Show Author Information

References

1

Vanacker H, Harter P, Labidi-Galy SI, et al. PARP-inhibitors in epithelial ovarian cancer: actual positioning and future expectations. Cancer Treat Rev. 2021;99:102255.
Crossref Google Scholar
2

Maiorano BA, Maiorano MFP, Lorusso D, Maiello E. Ovarian cancer in the era of immune checkpoint inhibitors: state of the art and future perspectives. Cancers (Basel). 2021;13(17):4438.
Crossref Google Scholar
3

Färkkilä A, Gulhan DC, Casado J, et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020;11(1):1459.
Crossref Google Scholar
4

Cosgrove J, Novkovic M, Albrecht S, et al. B cell zone reticular cell microenvironments shape CXCL13 gradient formation. Nat Commun. 2020;11(1):3677.
Crossref Google Scholar
5

Rubio AJ, Porter T, Zhong X. Duality of B cell-CXCL13 axis in tumor immunology. Front Immunol. 2020;11:521110.
Crossref Google Scholar
Genes & Diseases
Volume 11 Issue 5,
September 2024
Article number: 101200
DOI: 10.1016/j.gendis.2023.101200
Cite this article:
Ding Y, Ye Z, Ding B, et al. CXCL13 shapes tumor immune microenvironment in ovarian cancer with homologous recombination deficiency. Genes & Diseases, 2024, 11(5): 101200. https://doi.org/10.1016/j.gendis.2023.101200

128

Views

0

Downloads

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Altmetrics
Received: 09 April 2023
Published: 19 December 2023
© 2023 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Return